David G Winkler - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

David G Winkler

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Nature|November 8, 2016

PI3Kγ is a molecular switch that controls immune suppressionMegan M Kaneda, Karen S Messer, Natacha Ralainirina, et al.

Nature|December 16, 2016

Corrigendum: PI3Kγ is a molecular switch that controls immune suppressionMegan M Kaneda, Karen S Messer, Natacha Ralainirina, et al.

Journal of Medicinal Chemistry|March 4, 2025

Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome InhibitorDong-Ming Shen, Kate F Byth, Damien Bertheloot, et al.

Journal of Medicinal Chemistry|April 1, 2025

Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor"Dong-Ming Shen, Kate F Byth, Damien Bertheloot, et al.

ACS Medicinal Chemistry Letters|September 24, 2016

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical CandidateCatherine A Evans, Tao Liu, André Lescarbeau, et al.

Chemistry & Biology|November 12, 2013

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease modelsDavid G Winkler, Kerrie L Faia, Jonathan P DiNitto, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Nature|November 8, 2016

PI3Kγ is a molecular switch that controls immune suppressionMegan M Kaneda, Karen S Messer, Natacha Ralainirina, et al.

Nature|December 16, 2016

Corrigendum: PI3Kγ is a molecular switch that controls immune suppressionMegan M Kaneda, Karen S Messer, Natacha Ralainirina, et al.

Journal of Medicinal Chemistry|March 4, 2025

Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome InhibitorDong-Ming Shen, Kate F Byth, Damien Bertheloot, et al.

Journal of Medicinal Chemistry|April 1, 2025

Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor"Dong-Ming Shen, Kate F Byth, Damien Bertheloot, et al.

ACS Medicinal Chemistry Letters|September 24, 2016

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical CandidateCatherine A Evans, Tao Liu, André Lescarbeau, et al.

Chemistry & Biology|November 12, 2013

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease modelsDavid G Winkler, Kerrie L Faia, Jonathan P DiNitto, et al.

Pageof 2